{"id":"NCT02138916","sponsor":"AstraZeneca","briefTitle":"Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","officialTitle":"Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-13","primaryCompletion":"2018-04-10","completion":"2018-04-10","firstPosted":"2014-05-15","resultsPosted":"2019-06-13","lastUpdate":"2019-06-13"},"enrollment":1656,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Very Severe Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Benralizumab Arm A","otherNames":[]},{"type":"DRUG","name":"Benralizumab Arm B","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab Arm A","type":"EXPERIMENTAL"},{"label":"Benralizumab Arm B","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies","primaryOutcome":{"measure":"Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL","timeFrame":"From first IP to week 56","effectByArm":[{"arm":"Benralizumab 30 mg","deltaMin":1.19,"sd":null},{"arm":"Benralizumab 100 mg","deltaMin":1.03,"sd":null},{"arm":"Placebo","deltaMin":1.24,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.6490"},{"comp":"OG001 vs OG002","p":"0.0525"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":407,"countries":["United States","Austria","Canada","Czechia","Germany","Hungary","Italy","Japan","Netherlands","Poland","Romania","Russia","South Africa","South Korea","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["31575508","31112385"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2562&filename=Galathea_CSP_and_last_amendment_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2562&filename=D3251C00003_Statistical_Analysis_Plan_Redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":151,"n":554},"commonTop":["Viral upper respiratory tract infection","Bronchitis","Upper respiratory tract infection","Lower respiratory tract infection","Headache"]}}